Literature DB >> 33334894

Erythrocytes efficiently utilize exogenous sphingosines for S1P synthesis and export via Mfsd2b.

Toan Q Nguyen1, Thiet Minh Vu1, Farhana Tukijan1, Sneha Muralidharan2, Juat Chin Foo1, Jasmine Fei Li Chin3, Zafrul Hasan1, Federico Torta1, Long N Nguyen4.   

Abstract

Sphingosine-1-phosphate (S1P) is a potent lipid mediator that exerts its activity via activation of five different G protein-coupled receptors, designated as S1P1-5. This potent lipid mediator is synthesized from the sphingosine precursor by two sphingosine kinases (SphK1 and 2) and must be exported to exert extracellular signaling functions. We recently identified Mfsd2b as the S1P transporter in the hematopoietic system. However, the sources of sphingosine for S1P synthesis and the transport mechanism of Mfsd2b in erythrocytes remain to be determined. Here, we show that erythrocytes efficiently take up exogenous sphingosine and that a de novo synthesis pathway in part provides sphingosines to erythrocytes. The uptake of sphingosine in erythrocytes is facilitated by the activity of SphK1. By converting sphingosine into S1P, SphK1 indirectly increases the influx of sphingosine, a process that is irreversible in erythrocytes. Our results explain for the abnormally high amount of sphingosine accumulation in Mfsd2b knockout erythrocytes. Furthermore, we show that Mfsd2b utilizes a proton gradient to facilitate the release of S1P. The negatively charged residues D95 and T157 are essential for Mfsd2b transport activity. Of interest, we also discovered an S1P analog that inhibits S1P export from erythrocytes, providing evidence that sphingosine analogs can be used to inhibit S1P export by Mfsd2b. Collectively, our results highlight that erythrocytes are efficient in sphingosine uptake for S1P production and the release of S1P is dependent on Mfsd2b functions.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mfsd2b; S1P transporter; sphingosine; sphingosine-1-phosphate

Year:  2021        PMID: 33334894      PMCID: PMC7948482          DOI: 10.1074/jbc.RA120.012941

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

1.  Postnatal deletion of Spns2 prevents neuroinflammation without compromising blood vascular functions.

Authors:  Zafrul Hasan; Toan Q Nguyen; Brenda Wan Shing Lam; Jovi Hui Xin Wong; Caleb Cheng Yi Wong; Clarissa Kai Hui Tan; Jiabo Yu; Chung Hwee Thiam; Yongliang Zhang; Veronique Angeli; Long N Nguyen
Journal:  Cell Mol Life Sci       Date:  2022-10-05       Impact factor: 9.207

Review 2.  Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment.

Authors:  Alhaji H Janneh; Besim Ogretmen
Journal:  Cancers (Basel)       Date:  2022-04-27       Impact factor: 6.575

Review 3.  Sphingolipids in Hematopoiesis: Exploring Their Role in Lineage Commitment.

Authors:  Yasharah Raza; Huda Salman; Chiara Luberto
Journal:  Cells       Date:  2021-09-22       Impact factor: 7.666

4.  Murine endothelial serine palmitoyltransferase 1 (SPTLC1) is required for vascular development and systemic sphingolipid homeostasis.

Authors:  Andrew Kuo; Antonio Checa; Colin Niaudet; Bongnam Jung; Zhongjie Fu; Craig E Wheelock; Sasha A Singh; Masanori Aikawa; Lois E Smith; Richard L Proia; Timothy Hla
Journal:  Elife       Date:  2022-10-05       Impact factor: 8.713

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.